Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries

Damm, Oliver; Ultsch, Bernhard; Horn, Johannes; Mikolajczyk, Rafael T.; Greiner, Wolfgang; Wichmann, Ole

doi:10.1186/s12889-015-1861-8

Table 4 Vaccine characteristics and immunisation strategies considered in the models evaluating routine HZ vaccination

From: Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries

Study	Age at vaccination (in years)	Vaccine efficacy against HZ	Waning or duration of protection	Vaccination coverage^a	Vaccination costs per dose (2010 EUR, German price level)
Annemans et al. [65]	50+	37.6-63.9 %, age-dependent	No waning^b	20 %	EUR 141.39^c
Bilcke et al. [38]	60-85	Age-dependent (values are reported graphically only)	Consideration of waning depends on the choice of scenario	30 %	EUR 106.95^d
Bilcke et al. [30]	50 or 60	77 %^e	Duration of protection of 7.5 years or lifelong protection	30 % or 70 %	EUR 103.38^d
Bresse et al. [66]	65+	18-64 %, age-dependent	4.15 % per year and vaccine efficacy was set to zero after 10 years	20 %	EUR 117^f
Brisson et al. [67]	50-80	26-75 %, age-dependent	No waning^b	Not specified	EUR 108.60
de Boer et al. [40]	60-75	41.2-69.4 %, age-dependent	8.3 % per year (= duration of protection of 12 years)	Not specified	EUR 89.10^d
Edmunds et al. [68]	65	30-70 %	Duration of protection of 2.5 years to life long	60 %	EUR 122.13^d,g
Hornberger et al. [28]	69	Modelled by applying age-specific incidence of HZ in vaccine and placebo-treated arm of the clinical study, age-dependent	Duration of protection of 30 years	Not specified	EUR 43.85-438.46^d,h
Moore et al. [69]	50+	37.6-63.9 %, age-dependent	No waning^b	40 %	EUR 143.28^d
Najafzadeh et al. [26]	60+	Modelled by applying age-specific incidence of HZ in vaccine and placebo-treated arm of the clinical study, age-dependent	4.5 % per year	Not specified	EUR 101.83
Pellissier et al. [70]	60+	27.1-69.8 %, age-dependent	No waning^b	Not specified	EUR 147.32^d
Rothberg et al. [42]	60-80	Age-dependent	Waning considered but not quantified	Not specified	EUR 134.74^d
Szucs et al. [71]	70-79	37.60-63.9 %, age-dependent	No waning^b	20 %	EUR 143.09^d
Ultsch et al. [39]	50-80	13.22-69.8 %, age-dependent	8.3 % per year following 10 years of stable vaccine efficacy	20 %	EUR 147.48^d
van Hoek et al. [72]	60-75	31-95 % (based on 15 different take and waning scenarios), age-dependent	Duration of protection of 3.6-100 years (based on 15 different take and waning scenarios)	73.5 %	EUR 88.36^d
van Hoek et al. [33]	75	Data from van Hoek et al. [72]	Data from van Hoek et al. [72]	70 %	EUR 86.37^d
van Lier et al. [41]	60-80	Data from van Hoek et al. [72]	Duration of protection of 7.5 years	75 %	EUR 81.54^d

HZ herpes zoster
^aIn static models vaccination costs and effects are proportional to vaccination coverage. Hence, the level of coverage has no impact on the incremental cost-effectiveness ratio
^bBase-case analysis
^cIncluding co-payments
^dIncluding administration costs
^eThis value was assumed for the age group of 60–64 years. The supplemental material of this study also provides values for higher age groups (7-68 %) but no estimate is given for the age group below 60 years
^fReimbursement rate was assumed to be 65 % when taking a third-party payer perspective
^gCosts of an immunisation course comprising two doses
^hIncluding public awareness campaign, patient travel time, time receiving vaccine and costs of treating adverse events

Back to article page

ISSN: 1471-2458

Contact us

General enquiries: journalsubmissions@springernature.com

BMC Public Health

Contact us